| INTRODUCTION
Colorectal cancer (CRC) is one of the most common cancers in the world with approximately 1.3 million new cases diagnosed each year, and is a significant cause of cancer mortality. 1 Inherited factors are estimated to be involved in the development of one third of CRC cases. However, Mendelian CRC syndromes only explain about 5% of these cases. 2 These syndromes are caused by mutations or epimutations in well-known cancer susceptibility genes that include MLH1, PMS2, MSH2, MSH6, EPCAM, APC, SMAD4, BMPR1A, STK11, MUTYH, PTEN, KLLN, PIK3CA, AKT1, POLE, POLD1, AXIN2, BUB1 and BUB3. Mutations in high penetrance genes such as TP53 and CDH1
resulting in other cancer aggregations reveals ambiguous results in terms of their association with colorectal cancer risk. 3, 4 Four other genes, ATM, CHEK2, MLH3, and EXO1 (all associated with some aspect of DNA repair), have been implicated in CRC susceptibility. [5] [6] [7] [8] ATM and CHEK2 are increasingly being recognised as moderate penetrance genes primarily associated with an increased risk of breast cancer, but they have also been associated with CRC. 5, 7 The involvement of MLH3 and EXO1 in CRC is still disputed and if any effect at all, they are more likely to modify the risk of other high penetrant genes. 6, 8 Previous low-throughput sequencing studies aimed at investigating genes potentially involved in CRC susceptibility have identified candidates like GALNT12 and PTPRJ. 9, 10 However, these studies have not been replicated in additional independent cohorts and these genes require further validation before being included in the clinical management of CRC patients.
CRC is also considered as a complex disease, and low penetrant variants together with environmental factors are likely to be associated with the missing heritability apparent for the disease. Genomewide association studies (GWASs) have identified at least 31 common low-penetrant genetic variants associated with CRC susceptibility (reviewed in 11 ) . One GWAS has revealed that common variants in BMP4 influence CRC risk 12 which has been supported by a study that has potentially identified pathogenic germline mutations in BMP4 in early onset CRC patients with a family history of cancer. 13 It is therefore possible that rare coding variants in genes identified by GWAS can cause hereditary CRC.
Recent advances in sequencing technology have aided a highthroughput approach in the search for new genes involved in hereditary CRC. Four recent exome sequencing studies have identified several potential predisposition alleles. [14] [15] [16] [17] However, these studies only implicate potential candidates and require verification before these genes can be considered bone fide hereditary colorectal cancer genes.
In some families there is a clustering of CRC, which is suggestive of a hereditary predisposition. These families typically fulfil the Amsterdam I/II criteria (AM I/II) and/or the revised Bethesda guidelines (RBG), which were devised to help identify patients with Lynch Syndrome (LS) (MIM #609310, #120435, #614350, #614337) 18, 19 In this study, we included 274 patients who fulfilled the AM I/II criteria and/or the RBG. The patients had previously been referred for clinical genetic testing of 1 or more of the MMR genes (MLH1, PMS2, MSH2, MSH6), but no germline mutations were identified. The aim of this study was to find the genetic cause for the increased CRC risk in these unsolved cases, by using a gene-panel targeting 112 previously known or candidate CRC susceptibility genes.
| MATERIALS AND METHODS

| Samples
This study included DNA samples from 274 (82 Norwegian and 192 -Australian) familial CRC patients. Some of the individuals were related and altogether there were 8 families with 2 to 3 family members each (19 individuals). All patients fulfilled AMI/II and/or RBG and had previously been screened for mutations in 1 or more of the MMR genes (MLH1, PMS2, MSH2 and MSH6) without any pathogenic findings (80 of the Norwegian samples were also screened by MLPA). Some patients were also tested for other CRC-susceptibility genes, again without any pathogenic germline mutations being identified. Table 1 shows the clinical characteristics of the patients included in the study. 
| Data analysis
Analysis of sequencing data was performed as previously described 21 , with only minor variation. PCR duplicates were not removed from these datasets due to the use of restriction enzymes in the HaloPlex library preparation, leading to non-random fragmentation. Removing PCR duplicates at this step can lead to removal of~90% of reads. (Tables 2 and 3 ). The other 36 variants were found in candidate genes, where the association to CRC is yet to be clarified (Table 4 ). The 19 variants not confirmed by Sanger sequencing were mostly false positive frameshift variants, due to the remaining adapter sequences. All but 1 of the patients with Sanger validated variants fulfilled the Amsterdam criteria.
| Pathogenic variants in known CRC susceptibility genes
We found 17 pathogenic variants in 21 samples (Table 2 ). Of these, there were 4 mono-allelic MUTYH mutation carriers and 1 mono-allelic BLM mutation carrier. The mono-allelic BLM mutation carrier did not fulfil the Amsterdam criteria. One patient (no. 203) was bi-allelic for MUTYH mutation (NM_001128425; c.1187G>A and c.1227_1228dup).
When excluding the mono-allelic MUTYH and BLM mutation carriers, we found a most probable genetic explanation for the increased cancer risk in 16 (6%) of the patients' families using this multigene panel.
We identified 3 pathogenic (class 5) variants in the MMR genes MLH1 and MSH6 in 3 patient samples. The MSH6 (NM_000179.2) variant, c.3261dup (p.Phe1088Leufs*5) had previously been identified in a diagnostic setting and was included as a positive control.
The 2 other samples were originally classed as mutation negative for the MMR genes.
Two patients had pathogenic mutations in ATM, which is known to be a moderate penetrance gene that confers an increased risk of breast cancer. Both patients had a personal and family history of CRC, and 1 of the patients (no. 154) had breast cancer in the family.
The ATM variant c.8584+2T>C (NM_000051.3) was also tested, but One patient diagnosed with CRC at age 65 had a frameshift mutation in AXIN2. This patient is deceased, but abnormal dentition was reported, consistent with Oligodontia-colorectal cancer syndrome (MIM #608615).
One patient had a mutation in BRCA1 (no. 7) and 2 individuals in BRCA2 (no. 157 and 164). These 3 female patients were affected with early onset CRC. Two of them (nos 7 and 164) had a family history of CRC, breast and ovarian cancer, whereas the third (no. 157) had no family history of breast or ovarian cancer.
Two unique pathogenic variants were detected in 4 patients in POLE (NM_006231.3). In 3 of these patients a pathogenic POLE The PTEN missense variant is within a highly conserved catalytic domain, and it is reported to give rise to completely inactive protein.
26,27
The CHEK2 (NM_007194.3) variant (c.1100del, p.
Thr367Metfs*15) was found in a patient who was diagnosed with CRC at age 37. This CHEK2 variant is a well described, lower penetrant mutation, mainly associated with breast cancer, but also CRC and prostate cancer.
28,29
| Variants of unknown significance (VUS) in known CRC susceptibility genes
A total of 19 variants of unknown clinical significance were detected in 21 samples in known cancer susceptibility genes, and some of these may also prove to be pathogenic (Table 3) . and is predicted to abolish its function. Although, the physiochemical difference between Arg (positively charged) and Gly (no charge) is moderate (Grantham distance 125), the difference in size, hydrophobicity and charge between the wild-type and mutant residue is predicted to disturb hydrogen bonds (Cys891 and Asp932) and ionic interactions (salt bridges) (Glu819, Glu892 and Asp932) between residue 820 and these other internal residues. The loss of charge can also cause loss of interaction with other molecules. 32 The mutation is therefore likely to affect the function of the protein.
PIK3CA (NM_006218.2) VUS c.1729A>G (p.Arg577Gly) was found in a patient diagnosed with CRC at age 58 and 3 metachronous melanomas. Arg577 is highly conserved, it is predicted to be pathogenic by 6 prediction programs (PolyPhen, SIFT, MutationTaster, Align GVD, SNPs3D and UMD Predictor), and it located in the PIK domain which has been suggested to be involved in substrate presentation. As described above for the BUB1 mutation, the physicochemical difference between Arg and Gly is moderate (Grantham distance 125). However, this change is predicted to disturb ionic interactions (salt bridges) between PIK3CA residue 577 and Aspartic acid at position 395 and 578, indicating an effect on the protein's function. Norwegian individuals suggests that these variants are common in the Norwegian population. However, because these patients are highly selected the 2 PTEN variants may be pathogenic if they disrupt RNA Polymerase II binding, but this needs further investigation.
The variants in Table 3 with reported minor allele frequencies are less likely to be pathogenic, except for that identified in BLM, which is associated with recessive disease. In addition, segregation analysis of the MSH2 variant c.138C>G (p.His46Gln) and PMS2 c.1004A>G (p.Asn335Ser) does not support pathogenicity. However, PMS2 is found to have much lower penetrance for CRC than the other MMR genes, and therefore mutations may not always be associated with disease. 33 For the remaining variants listed in Table 3 , there is no further information indicating whether they are pathogenic or benign.
| Variants in candidate CRC genes
We identified 37 unique variants in 36 different patients in candidate genes that have a potential role in CRC susceptibility (Table 4) 
| DISCUSSION
In this study, we found several pathogenic or likely pathogenic (class 4-5) variants in known cancer susceptibility genes, which validates our approach for identifying disease causing variants. Some of the VUS's revealed in this study may also prove to be pathogenic, as more becomes known about the functional impact of these variants.
Three variants in MLH1 and MSH6 as well as a number of variants of unknown significance (VUS) were identified in our sample set. The most likely explanation for this finding is the accuracy of some of the screening protocols that were used to identify variants in known MMR genes. Using high-throughput screening approaches that are significantly more accurate than previous methodologies it is to be expected some additional mutations in these genes will come to light. We recommend that samples screened by methodologies that do not employ direct DNA sequencing be re-evaluated by better more cost-effective and accurate assays. ).
This makes it more difficult to choose the appropriate gene(s) to test.
By using multigene panels, all relevant genes can be tested simultaneously, increasing the probability of finding a causal variant. An example in this study is patient no. 7 in which we discovered the pathogenic BRCA1 variant c.4096+3A>G. This patient and a first degree relative were both affected with CRC and consequently this patient was, at that time, only tested for MMR genes. There was also a case of bilateral breast cancer and 2 cases of ovarian cancer in this family, but the 2 CRC cases in the index patient and her parent suggested a CRC predisposition rather than a breast ovarian cancer family.
Another advantage by using a broader gene panel testing approach is that it may reveal whether there is more than 1 pathogenic variant in a high-risk family. Mutations in different genes in 1 family may explain an untypical spectrum spectre of cancer types in a family. 38, 39 These patients are at risk for not being tested for LS.
We identified several potentially pathogenic variants in previously proposed candidate CRC susceptibility genes thereby increasing the evidence that they are associated with disease risk.
Notwithstanding, additional studies on these genes are required to unequivocally define them as CRC susceptibility genes. Although we have narrowed the list down to some interesting candidates (indicated in Table 4 ), we could not confirm any of the proposed candidate CRC susceptibility genes due to the absence of additional family members participating in this study. The POLE variant c.229C>T (p.
Arg77Cys) exemplifies this point, where additional family members appeared to confirm the association. Owing to the paucity of data on what it actually means to harbour a potential causative variant in any of the genes we have identified, we do not recommend the inclusion of candidate genes in a diagnostic setting, as they would only confuse an already complex situation.
For many of the patients we did not find any genetic explanation for their increased CRC risk. The cause for CRC susceptibility in these patients may be found in non-coding regions of the genes of interest or could be explained by copy number variations, which were not addressed in this study. Alternatively, the mutational yield was not particularly high in this study suggesting that other variants are located in genes not targeted by our panel design. These unexplained cases are candidates for exome and whole-genome sequencing.
In conclusion, we have identified a most probably genetic cause for the increased risk of CRC for 17 (6%) of the patients included in this study. We have also identified some variants both in known-and candidate CRC susceptibility genes which should be the subject of further research to determine their involvement in CRC risk. Overall, the results show that gene panel sequencing is a more effective method by which to identify pathogenic germline variants in CRC patients compared with a single gene approaches.
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